Stanford, California 94305

  • Multiple Myeloma


Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish mixed chimerism using low dose total body irradiation along with immunosuppression using cyclosporine and mycophenolate mofetil; suppress graft-vs-host and host-vs-graft reactions to allow a mixed chimeric state to be established, encourage tolerance and prevent graft-vs-host disease (GvHD) during the mixed chimerism period and use donor lymphocyte infusions to convert the patient to a full chimera while developing a graft-vs-tumor effect.

Study summary:

Participants are mobilized with cyclophosphamide 4 g/m2 and filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue [ie, autologous hematopoietic cells transplant (auto-HCT)]. Post-infusion support includes filgrastim 5 µg/kg/day, starting 6 days following melphalan. Participants with stable or responsive disease at 4 weeks eligible to continue on to the planned allogenic HCT (allo-HCT). For allo-HCT, a sibling donor that is fully matched for human leukocyte antigen (HLA-matched) is identified. Participants receive a single dose of total body irradiation (TBI) 200 centigray (cGy) as well as immunosuppression with cyclosporine (CSP) 6.25 mg/kg and mycophenolate mofetil (MMF) 15 mg/kg. The HLA-matched donor begins filgrastim injections 16 µg/kg/day on day -4 continuing to Day 0, with apheresis collections on Day -1 and Day 0, to a target of > 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV and diphenhydramine 50 mg IV. CSP will be tapered beginning Day 56 with a goal of discontinuing CSP on Day 180, adjusted as needed.


PATIENT INCLUSION CRITERIA - Multiple myeloma, early Stage II-III or relapsed / progression after initial treatment of Stage I disease - Patient has HLA-identical sibling donor - Age ≤ 70 years - No prior therapy which would preclude the use of low-dose total body irradiation - Pathology review and diagnosis confirmation by Stanford University Medical Center - Karnofsky performance status (KPS) > 70% - DLCO ≥ 60% predicted - ALT and AST < 2 x upper limit of normal (ULN) - Total bilirubin < 2 mg/dL - Serum creatinine < 2.0, or 24-hour creatinine clearance ≥ 60 mL/min - HIV-negative - Signed informed consent document PATIENT EXCLUSION CRITERIA - Smoldering multiple myeloma; monoclonal gammopathy of unknown significance; or primary amyloidosis - Severe psychological or medical illness - Prior allogeneic hematopoietic cell transplantation - Pregnant or lactating ALLOGENEIC DONOR INCLUSION CRITERIA - Age ≥ 17 - HIV-seronegative - Signed informed consent document ALLOGENEIC DONOR EXCLUSION CRITERIA - Serious medical or psychological illness - Pregnant or lactating - Prior malignancies within the last 5 years, except for non-melanoma skin cancers



Primary Contact:

Principal Investigator
Wen-Kai Weng, MD
Stanford University

Backup Contact:


Location Contact:

Stanford, California 94305
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.